Outcome in cadaveric renal transplant recipients treated with cyclosporine a and mycophenolate mofetil versus cyclosporine a and azathioprine

Journal of Surgical Research

Volumn 76, Issue 2, 1998, Pages 131-136

  Lee, Crystine M ^a   Markezich, Amy J ^b   Scandling, John D ^c   Dafoe, Donald C ^b   Alfrey, Edward J ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

CADAVER; CELL PROLIFERATION; CONFERENCE PAPER; GLYCOSYLATION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; PRIORITY JOURNAL; PURINE SYNTHESIS; RECIPIENT; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 0032079185     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1998.5307     Document Type: Conference Paper

References (15)

1. Allison A. C., Eugui E. M. Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin. Transplant. 7:1993;96.
2. Sollinger H. W. Update on preclinical and clinical experience with mycophenolate mofetil. Transplant. Proc. 28:1996;24.
3. Eugui E. M., Allison A. C. Immunosuppressive activity of mycophenolate mofetil. Ann. N.Y. Acad. Sci. 685:1993;309.
4. Häyry P. Pathophysiology of chronic rejection. Transplant. Proc. 28:1996;7.
5. Gulaniker A. C., MacDonald A. S., Sungurtekein U., Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation. 53:1992;323.
6. Sollinger H. W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 60:1995;225.
7. Lancet. 345:1995;1321.
8. Transplantation. 61:1996;1029.
9. Knechtle S. J., Heisey D. M., Pirsch J. D., D'Alessandro A. M., Kalayoglu M., Sollinger H. W. Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation. Surgery. 120:1996;719.
10. Halloran P., Mathew T., Tomlanovich S., Groth C., Hooftman L., Barker C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation. 63:1997;39.
11. Deierhoi M. H., Sollinger H. W., Diethelm A. G., Belzer F. O., Kauffman R. S. One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation. Transplant. Proc. 25:1993;693.
12. Sollinger H. W., Belzer F. O., Deierhoi M. H., Biethem A. G., Gonwa T. A., Kauffman R. S. RS-61443 (mycophenolate mofetil): A multicenter study for refractory kidney transplant rejection. Ann. Surg. 216:1992;513.
13. Tomlanovich S. J. Rescue therapy with mycophenolate mofetil. Transplant. Proc. 28:1996;34.
14. Shen G. K., Alfrey E. J., Knoppel C. L., Dafoe D. C., Scandling J. D. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous gangciclovir in kidney and kidney/pancreas transplantation. Transplantation. 64:1997;931.
15. Alfrey E. J., Lee C. M., Scandling J. D., Pavlakis M., Markezich A. J., Dafoe D. C. When should expanded criteria kidneys be used for single versus dual kidney transplants. Transplantation. 64:1997;1142.